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ABSTRACT
We previously reported that autocrine TNF-α (TNF) is responsible for JNK 
pathway activation in a subset of acute myeloid leukemia (AML) patient samples, 
providing a survival/proliferation signaling parallel to NF-κB in AML stem cells (LSCs). 
In this study, we report that most TNF-expressing AML cells (LCs) also express 
another pro-inflammatory cytokine, IL1β, which acts in a parallel manner. TNF was 
produced primarily by LSCs and leukemic progenitors (LPs), whereas IL1β was mainly 
produced by partially differentiated leukemic blasts (LBs). IL1β also stimulates an 
NF-κB-independent pro-survival and proliferation signal through activation of the JNK 
pathway. We determined that co-inhibition of signaling stimulated by both TNF and 
IL1β synergizes with NF-κB inhibition in eliminating LSCs both ex vivo and in vivo. 
Our studies show that such treatments are most effective in M4/5 subtypes of AML.
INTRODUCTION
Acute myeloid leukemia (AML) is a common 
hematopoietic malignancy in adults. Incidence is 
increased in aged populations with average age of 67 
years at diagnosis. Intensive chemotherapy is the standard 
treatment for AML (except for M3 subtype), which 
can induce complete remission in 40-70% of patients. 
However, such treatment cannot eliminate AML stem 
cells (LSCs) in almost all cases, and the remaining 
LSCs, described as minimal residual diseases (MRD), 
can reconstitute the tumor by producing new leukemic 
progenitors (LPs) and leukemic blasts (LBs). Thus, almost 
all AML patients will succumb to disease relapse due to 
drug-resistant LSCs and their progeny. Currently, 5-year 
overall survival for AML patients is 40 to 45% for patients 
under 60 years of age, and <10% for patients 60 years of 
age and older [1–4]. In addition, intensive chemotherapy 
is limited in older patients due to life-threatening 
inflammation-mediated complications and side effects 
[5, 6]. Therefore, the development of more specific and 
efficient targeting strategies for eliminating LSCs in AML 
treatment is urgent.
NF-κB is a key transcriptional regulator of 
inflammatory cytokine-stimulated signaling and plays 
a central role in the development and progression of 
inflammation-associated cancer [7–10]. NF-κB is also 
required for maintenance of LSCs. In AML, tumor necrosis 
factor-α (TNF hereafter) and NF-κB promote LSC survival 
and proliferation in a feed-forward manner [11]. While 
NF-κB activity is undetectable in unstimulated normal 
CD34+ hematopoietic stem/progenitor cells (HSPCs), it 
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is constitutively activated in CD34+CD38- LSCs isolated 
from almost all AML patients [12–14]. Also, inactivation 
of NF-κB signaling selectively eradicates LSCs in vitro 
especially when combined with chemotherapeutic drugs 
without significant influence on the survival and growth 
of normal HSPCs [15]. This suggests that targeting NF-κB 
could be an effective treatment paradigm for eliminating 
LSCs. However, the anti-leukemia effects of NF-κB 
inhibition in clinical patients are inadequate, suggesting 
a protective mechanism exists within the bone marrow 
environment.
We reported that in many subtypes of AML, 
especially in M4 and M5, the anti-leukemia effects of NF-
κB inhibition are attenuated by autocrine TNF stimulation 
of JNK (a survival/proliferation signal in LCs) and 
paracrine TNF stimulates a JNK-mediated necroptotic/
apoptotic signal in HSPCs [16]. We determined that 
inhibition of TNF-JNK signaling provided improved 
treatment for TNF-expressing AML when combined with 
NF-κB inhibitors. We also found that co-inhibition of 
JNK and NF-κB signaling was also effective in some TNF 
non-expressing LCs and patient samples, suggesting that 
other cytokines might be secreted by LCs which can also 
activate JNK signaling in addition to TNF [16].
In this study, we found that in addition to TNF, most 
LCs, especially M4 and M5 LCs, also secrete interleukin 
1β (IL1β). IL1β stimulation of both NF-κB and JNK 
signaling protects LSCs and LPs from NF-κB inhibition 
by compensating TNF signaling. Our study suggests that 
inhibition of both TNF and IL1β signaling could represent 
an improved treatment for inflammatory cytokine-
secreting AML when combined with an NF-κB inhibitor.
RESULTS
TNF signaling inactivation only slightly 
potentiated the anti-leukemic effects of NF-κB 
inhibitor in vivo
We reported that TNF stimulates JNK signaling to 
protect LCs from NF-κB inhibition as shown in primary 
patient samples, human AML cell lines and MLL-AF9 
(MA9)-transduced murine LCs. Inhibition of either TNF 
or JNK could significantly increase the sensitivity of LCs 
to NF-κB inhibitor treatment in vitro [16]. Consistent with 
this observation, we found that combined treatment with 
both the NF-κB inhibitor BAY11-7802 (BAY hereafter) 
and the JNK inhibitor SP600125 (SP hereafter) profoundly 
reduced the tumor burden and prolonged the survival of 
leukemic mice developed from MA9 transduction (Figure 
1A-1C). Currently, there are no clinically available JNK 
inhibitors approved for use in human subjects; however 
many TNF blockers have been developed for the clinical 
treatment of inflammatory diseases such as arthritis [17]. 
Therefore, we tested whether inhibition of TNF can also 
sensitize LCs to NF-κB inhibition in vivo by transplanting 
Tnfr-/- LCs (genomic deletion of Tnfr1/2) into sub-lethally 
irradiated mice and treating with NF-κB inhibitor – 
(Figure 1D-1F). Consistent with the results of our previous 
study [16], mice which had received Tnfr-/- LCs required 
longer latency for leukemia development than mice which 
had received WT LCs (Supplementary Figure 1). We 
found that, compared to the vehicle-treated group, NF-
κB inhibition was able to slightly extend the lifespan of 
mice which had received Tnfr-/- LCs, while a combination 
of JNK or NF-κB inhibitors also significantly reduced the 
tumor burden and prolonged the life of Tnfr-/- leukemic 
mice (Figure 1D–1F). These data suggested that in 
addition to TNF, other cytokine(s) might also protect LCs 
from NF-κB inhibition in vivo by stimulating JNK.
The sensitivity of LSCs and LPs to NF-κB 
inhibition in culture was dependent on cell 
density
Using purified LSCs, which are normally cultured in 
in vitro studies at a relatively low density, previous studies 
demonstrated that LSCs are highly sensitive to NF-κB 
inhibitor treatment [12, 13]. In our previous studies, we 
also cultured LCs at a relatively low density (1-2×105/
ml). To examine the responses of LSCs and LPs to NF-κB 
inhibition, we used an unpurified mixed population of LCs 
containing LSCs, LPs and partially differentiated LBs in 
our studies because we believed that such a mixture of 
cells would be more representative of the real situation 
of LCs in patient bone marrow tissues. MA9-transduced 
murine LCs were used as a model system in our studies 
because LPs and LSCs among such LCs can be reliably 
evaluated by colony-forming unit (CFU) assay and in vivo 
transplantation assay, respectively [16, 18].
To test whether cell density influences the response 
of LCs to NF-κB inhibition, we incubated LCs at indicated 
densities with or without 100nM BAY for 12 hours. Cells 
were then collected and seeded into methylcellulose 
for CFU (Supplementary Figure 2). We found that the 
sensitivity of LCs to NF-κB inhibitor treatment is dependent 
on cell density. We then treated LCs in high density (HD, 
5×105/ml) and low density (LD, 1×104/ml) conditions with 
indicated dosages of BAY for 12 hours. Cells were then 
collected for CFU (Figure 2A) or injected into lethally-
irradiated receipt mice for transplantation studies (Figure 
2B). We found that, consistent with previous studies, LPs 
(Figure 2A) and LSCs (Figure 2B) are highly sensitive to 
BAY treatment in LD culture, as demonstrated by CFU 
assay and ex vivo treatment followed by transplantation. 
BAY treatment induced significant apoptosis in LCs in the 
LD condition, as shown by cell morphology (Figure 2C) 
and Annexin-V staining (Figure 2D). Tnfr-/- LCs are more 
sensitive to NF-κB inhibitor treatment compared to WT 
LCs in such LD conditions (Figure 2E). However, when 
cultured in HD conditions, the killing effects of NF-κB 
inhibition on LPs (Figures 2A, 2E) and LSCs (Figure 1B) 
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were significantly attenuated in both WT and Tnfr-/- LCs. 
However, the sensitivity of LPs to the NF-κB inhibitor 
could be largely restored by JNK inhibition (Figure 2E and 
Supplementary Figure 3), further supporting the notion that, 
in addition to TNF, other factors secreted by LCs might 
also provide protection to LPs and LSCs [16, 19] through 
activation of JNK. To further support this notion, we found 
that JNK signaling was more highly activated in WT LCs 
than in Tnfr-/- LCs when cultured in LD condition. However, 
in HD culture, JNK signaling was comparable between WT 
and Tnfr-/- LCs (Figure 2F).
IL1 promoted the growth of LPs independent of 
TNF
To search for these other autocrine factors that can 
activate JNK targets and counteract the anti-AML effects 
of NF-κB inhibitors, we first analyzed the expression 
profile of inflammatory cytokines in 580 primary human 
AML samples in our microarray data (Figure 3A). 
Although the expression levels of TNF are generally 
elevated in M3/4/5AML cells compared to normal 
HSPCs, a subset of M4 and M5 AML samples also express 
much higher levels of IL1 (both α and β). We confirmed 
in newly-diagnosed M4/5 subtype AML patients that 
there were increased levels of pro-inflammatory 
cytokines TNF and IL-1 in their peripheral blood (Figure 
3B), which correlated to the increased TNF and IL1 
expression by CD34+ tumor cells (Figure 3B). We also 
determined that MA9-transduced murine LCs expressed 
and produced endogenous TNF and IL1β (Figure 3D). 
Consistent with a previous study [11], we found that TNF 
is highly expressed in c-kit+ LSCs and LPs (Figure 3E). 
In addition, we found that IL1β is highly expressed in 
Figure 1: Inactivation of TNF failed to sensitize LCs to NF-κB inhibition in vivo. WT LCs A-C. and Tnfr-/- LCs D-F. were 
transplanted into sub-lethally irradiated mice. Schematic diagram of the experimental procedures (A, D). On day 15 post-transplantation, 
mice were randomly divided into four groups and were treated with vehicle, 30 mg/kg SP6 or 10mg/kg BAY individually or in combination 
daily for 10 days. Livers were collected from recipient mice on day 30 post-transplantation for WT LCs (B-C) and on day 40 post-
transplantation for Tnfr-/- LCs (E-F). Three mice from each group were analyzed. Infiltration of LCs was examined by H & E staining 
of liver sections. The ratio of liver/body weight was presented. Bars, 200μM. Survival of the recipient mice was analyzed by Kaplan-
Meier survival graphing (A, D). Numbers of mice used in each group were noted. Leukemia was confirmed at the time of death of 
each transplanted mouse. * indicates p<0.05 when compared to vehicle-treated control. # indicates p<0.05 when compared to Bay or SP 
individual inhibitor-treated groups.
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c-kitlow/- partially-differentiated LBs compared to c-kit+ 
LSCs/LPs (Figure 3E). In human primary LCs, TNF was 
highly expressed in CD34+ LSCs and LPs, while IL1β was 
highly expressed in CD34- LBs (Figure 3F). Significantly 
higher concentrations of IL1β were detected in LC culture 
medium when cultured in HD conditions than when 
cultured in LD conditions (Figure 3G).
We found that IL1β can induce JNK signaling 
independent of TNF signaling (Figure 4A). To 
study whether IL1β can promote the growth of LCs 
independently of TNF, we treated MA9-transduced 
Tnfr-/- LCs and MA9-transduced Tnfr wild-type LCs (WT 
LCs hereafter) with IL-1β and measured proliferation 
and colony formation. We observed that IL1β promotes 
proliferation (Figure 4B) and colony-forming ability 
in both Tnfr-/- and WT LCs in a dose-dependent fashion 
when <50ng/ml of IL1β was used (Figure 4C). IL-1 
doses >50 ng/mL did not further enhance CFUs in LCs. 
Although IL1β also promotes the clone-forming capacity 
of HSPCs (Figure 4D), we found that it compromises 
the hematopoietic reconstitutive ability of hematopoietic 
stem cells (HSCs) as demonstrated by ex vivo treatment 
and transplantation studies (Figure 4E). This suggests that 
although IL1β promotes the colony-forming ability of 
normal progenitors, it represses HSC function. We then 
treated the LCs with a combination of IL1RA, a natural 
IL1 antagonist, and anti-TNF, a TNF neutralizing antibody. 
We found that the combined inhibition of IL1β and TNF 
signaling had an additive, dose-dependent repressive effect 
on CFU in LCs (Figure 4F). We confirmed this conclusion 
by treating Tnfr-/- LCs with IL1RA (Figure 4G). To verify 
the specificity of IL1RA treatment, we knocked down 
IL1 receptor-1 (IL1R) in LCs by shRNA (Figure 4H). 
We found that genetic inhibition of IL1R also sensitized 
LCs to anti-TNF treatment (Figure 4I). LCs with IL1R 
knockdown generated far fewer CFUs in the presence of 
anti-TNF when compared to Scr-shRNA-transduced LCs.
Combined inhibition of TNF and IL1 sensitized 
LPs and LSCs to NF-κB inhibition in high-
density culture condition
Since both TNF and IL-1 stimulate the activation 
of JNK [16] (Figure 4A), we treated WT LCs in HD 
condition with IL1RA or anti-TNF individually or in 
combination for CFU assay in the presence or absence 
Figure 2: Inactivation of TNF failed to sensitize LSCs and LPs to NF-κB inhibition in vitro when cultured at high 
density. WT LCs were cultured at low density (1×104/ml, LD) or high density (5×105/ml, HD) and treated with indicated concentrations 
of BAY for 12 hours. Cells were collected for colony-forming assay, A. transplanted into recipient mice for leukemia development B., cell 
morphology (the numbers presented in each photo are the percentage of morphologically apoptotic cells) C., or cell death by Annexin-
V/7AAD staining D. The numbers of cells seeded per plate or transplanted per mouse were based on the number of initial treated cells. 
Results shown are indicative of three independent trials in (A). Five mice were used in each treatment group in (B). ** indicates p<0.01 
when compared to vehicle controls. ## indicates p<0.01 when compared to HD groups with the same dosage of BAY. E. WT and Tnfr-/- LCs 
were incubated at LD (1×104/ml) or HD (5×105/ml) and were treated with 200nM Bay, 10μM SP6 or both in combination for 12 hours and 
then collected for CFU assay. Vehicle-treated cells were used as controls. * indicates p<0.05 when compared to vehicle-treated controls. 
$ indicates p<0.05 when compared to WT LCs. # indicates p<0.05 when compared to HD groups with same treatments. & indicates p<0.05 
when compared to HD groups with Bay or SP individual treatment. F. WT (lanes 1 and 3) and Tnfr-/- LCs (lanes 2 and 4) were incubated at 
LD (1×104/ml) or HD (5×105/ml) for 24 hours. JNK and NF-κB signaling activity were compared by Western blotting.
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Figure 3: Expression of both TNF and IL1β in many types of LCs. A. Expression of TNF, TNFR, IL-1, IL-1R, c-JUN and JUNB 
in primary human AML samples was compared by microarray. B. TNF and IL-1 protein levels in PB of AML patients were examined by 
ELISA. C. TNF and IL-1 mRNA in primary AML samples were examined by qRT-PCR assay. D. Schematic for development of murine 
MA9- and Runx1-Eto-9a LCs. TNF and IL1β expression was examined by Western blotting. Each lane was from LCs from a separate 
transplanted mouse. E. Expression of TNF and IL1β in c-kit+ LSCs/LPs and c-kitlow/- LBs isolated from murine MA9-LCs were examined 
by qRT-PCR. F. Expression of TNF and IL1β in CD34+ LSCs/LPs and CD34low/- LBs isolated from 4 primary AML patient samples was 
examined by qRT-PCR. G. MA9-LCs were cultured in LD or HD conditions. IL1β concentration was examined in the culture medium at 
indicated times of incubation.
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Figure 4: IL-1 promotes the growth of clonogenic LPs. A. WT, Tnfr-/-, Rip1-/- LCs were treated with IL1β for 15 minutes. JNK 
activity was examined by Western blotting. B. WT LCs and Tnfr-/- LCs cultured in LD condition (1×104/ml) and treated with 50ng/ml of 
IL1β. Twelve hours after treatment, cells were treated with 10μM BrdU for an additional 2 hours. Cells were collected for BrdU staining 
using APC BrdU Flow Kits (BD Pharmingen) following the protocol provided by the vender. * indicates p<0.05 compared to untreated 
WT LCs. # indicates p<0.05 compared to untreated controls. C. WT and Tnfr-/- LCs were cultured in LD condition (1×104/ml) and treated 
with increasing concentrations of recombinant IL-1β for 12 hours. Cells were then were seeded for CFU assay. D. Normal bone marrow 
mononuclear cells (MNCs) were treated with increasing concentrations of IL1β for 12 hours and then seeded for CFU assay. E. One million 
bone marrow MNCs were isolated from normal CD45.1+ mice and treated with indicated concentrations of IL-1β for 24 hours. Treated 
cells were mixed with 1×106 support MNCs (CD45.2+) and transplanted into lethally-irradiated recipient mice (CD45.2+) to evaluate 
hematopoietic reconstitutive capacity. Five mice were used in each treatment group. F. WT LCs were cultured in HD condition (5×105/ml) 
and treated with 20ug/ml of anti-TNF and indicated doses of IL-1RA for 12 hours. Cells were collected and seeded for CFU. G. WT and 
Tnfr-/- LCs were cultured in HD condition and treated with increasing concentrations of IL-1RA for 12 hours. Cells were collected for CFU 
assay. H. shRNA knockdown of IL-1 receptor 1 (IL-1R1) in LCs as determined by qRT-PCR. I. LCs transduced with shRNAs specific for 
IL-1R (sh-IL-1R-1 and sh-IL-1R-2) were cultured in HD condition and treated with or without 20ug/ml of anti-TNF. Twelve hours hence, 
cells were seeded for CFU assay. Scrambled (Scr)-shRNA transductions were studied in parallel as controls. * indicates p<0.05 when 
compared to 0ng/ml IL1β group (C-E), or 0ng/ml IL1RA groups (F, G), or Scr groups (H, I). # indicates p<0.05 when compared to WT 
LCs (C, G), and vehicle groups (F, I) as determined by one-way ANOVA.
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of the NF-κB inhibitor BAY for 12 hours and seeded 
them for CFU. We found that while IL1RA or anti-TNF 
alone can repress the CFU of LCs, combination treatment 
significantly enhances the CFU inhibitory activity of the 
NF-κB inhibitor, suggesting that co-inactivation of IL1 
and TNF signaling can significantly sensitize LCs to NF-
κB inhibition in HD culture condition (Figure 5A). We 
confirmed this conclusion by treating Tnfr-/- LCs with 
IL1RA and BAY alone or in combination (Figure 5B). 
We also further confirmed the conclusion by treating 
IL1R-knockdown LCs with anti-TNF and BAY alone 
or in combination (Figure 5C). However, inhibition of 
both TNF and IL-1R signaling did not enhance the CFU 
inhibitory activity of the JNK inhibitor, suggesting that 
TNF and IL-1 are the primary stimuli for JNK in LCs 
(Supplementary Figure 4).
We then determined that treatment of LCs with 
IL1RA, anti-TNF, or BAY alone or in the indicated 
Figure 5: LSCs and LPs with both TNF and IL-1 signaling inactivation are much more sensitive to NF-κB inhibition 
than are LSCs and LPs with inactivation either of the cytokine signaling alone. A. WT LCs were cultured in HD condition 
(5×105/ml) and treated with 20ug/ml of anti-Tnf, 500ng/ml IL-1RA, 150nM BAY individually or in combination for 12 hours, and then 
seeded into methylcellulose for CFU assay. Vehicle treatment was used as a control. B. WT LCs and Tnfr-/- LCs in HD condition were 
treated with 500ng/ml IL-1RA and 100nM of BAY individually or in combination for 12 hours and seeded for CFU assay. C. sh-IL-1R-
1-transduced LCs (as described in Figure 4G) cultured in HD condition were treated with 100nM BAY or anti-TNF for 12 hours and 
then seeded for CFU assay. Scrambled shRNA (Scr) transductions were studied in parallel as controls. D. WT LCs were cultured in HD 
condition (5×105/ml) and treated with 20ug/ml of anti-Tnf, 500ng/ml IL-1RA, 100nM BAY individually or in indicated combinations for 
12 hours. Cells were collected and transplanted to assess leukemogenic ability. Vehicle treatment was used as a control. E. Tnfr-/- LCs were 
cultured in in HD condition (5×105/ml) and treated with 500ng/ml IL-1RA or 100nM BAY individually or in combination for 12 hours. 
Cells were collected and transplanted to assess leukemogenic ability. Two thousand initial cells were transplanted into lethally-irradiated 
recipient mice with BM support cells. Survival of the recipient mice was analyzed by Kaplan-Meier survival graphing. Results shown 
for (A-C) are representative of three independent trials. * indicates p<0.05 when compared to vehicle control; # indicates p<0.05 when 
compared to individual chemical treatment groups; & indicates p<0.05 when compared to two chemical combination groups. Statistical 
significance was determined by one-way ANOVA with Bonferonni post-hoc test.
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combinations ex vivo had effects specific to LSCs by 
performing ex vivo treatment followed by transplantation. 
After 24 hours of indicated treatments, LCs were 
collected for cell death analysis and transplanted into 
recipient mice to observe for leukemia development 
(Figure 5D). Each mouse was transplanted with 2×103 
of the initial LCs. Mice were then observed for leukemia 
development. A significant increase in cell death was 
detected in IL1RA, anti-TNF, or BAY single-treated 
LCs when compared to vehicle treated control; cell 
death was further increased in any of the two drug 
combination groups and even further increased in the 
three drug combination condition (Supplementary Figure 
5a). As a consequence, we found that disease onset in 
mice that had received either IL1RA, anti-TNF, or BAY 
single-treated LCs was significantly delayed compared 
to mice receiving vehicle-treated LCs, and was even 
further delayed in mice receiving LCs treated with any 
of these two chemical combinations. Most importantly, 
mice receiving all three chemically-treated LCs survived 
longest, with 3 out of 8 mice surviving over 135 days 
without any sign of leukemia (Figure 5D). This study 
suggested that co-inhibition of TNF and IL-1 signaling 
significantly enhanced the ability of NF-κB inhibitor to 
eliminate LSCs. We confirmed these results by combined 
treatment of Tnfr-/- LCs with IL1Ra and BAY ex vivo 
(Figure 5E). IL1RA or BAY treatment induced significant 
cell death in Tnfr-/- LCs. Significantly more cell death 
was detected in the IL1RA and BAY combination 
group (Supplementary Figure 5b). Consistent with this 
observation, mice receiving BAY or IL1RA-treated Tnfr-/- 
LCs required a significantly longer latency for leukemia 
development than mice receiving vehicle-treated Tnfr-/-
 LCs. Mice which had received BAY plus IL1RA treated 
Tnfr-/- LCs survived much longer, with 5 out of 8 mice 
surviving over 135 days without any sign of leukemia. 
Taking together, our data suggest that inactivation 
of both IL1 and TNF signaling is more effective in 
facilitating NF-κB inhibitor-mediated LSC elimination 
than inactivation of either alone (Figure 5E).
Combined inhibition of TNF/IL1 and NF-κB 
repressed leukemia development in vivo
To evaluate the anti-leukemia effect of the 
combined treatment in vivo, we generated murine 
leukemia by transplanting WT LCs into recipient mice. 
These mice were treated with the indicated drugs 15 
days following transplantation. We found that treatment 
with any of the single drugs in our study reduced disease 
burden as shown by reduced liver infiltration (Figure 
6B, 6C) and prolonged survival by one week (Figure 
6A), with any double inhibitor treatment prolonging 
survival by another week. Triple inhibition of TNF, 
IL1, and NF-κB profoundly reduced the disease burden 
and prolonged survival by a maximum of 90 days 
(Figure 6A). We confirmed these results by combined 
treatment of Tnfr-/- LCs with IL1RA and BAY (Figures 
6D-6F). In vivo treatment demonstrated that mice 
which had received Tnfr-/- LCs survived significantly 
longer after treatment with BAY and IL1RA in 
combination than mice treated with either BAY or 
IL1RA individually (Figure 6D) due to the much more 
significant repression of disease progression as shown 
by reduced liver infiltration of LCs (Figure 6C, 6D). 
Taken together, our data suggest that inactivation 
of both IL1β and TNF signaling is more effective in 
facilitating NF-κB inhibitor-induced repression of 
leukemia development. Our data suggested that the 
anti-leukemia effect of NF-κB inhibition in vivo can be 
significantly enhanced by inhibition of either TNF or 
IL1 signaling alone, and can be further promoted by 
co-inhibition of both TNF and IL1 signaling (Figure 6).
Inactivation of individual AP1 factors reduced 
colony-forming ability and promoted the 
sensitivity of LCs to NF-κB inhibition
We have reported that TNF induces necroptosis/
apoptosis in normal HSPCs by stimulating a prolonged 
activation of JNK signaling. However, in LCs, the 
expression of MKP5 turns off JNK signaling shortly 
after its activation. Thus, TNF induces only a transient 
JNK activation in LCs [16]. Such transitory activation 
of JNK promotes the proliferation and survival of LCs 
by activating downstream transcription factors, such as 
the AP1 family. Upon stimulation with TNF or IL1β, 
c-Jun, JunB and JunD were activated in LCs as shown by 
increased phosphorylation of these proteins (Figure 7A). 
To determine which AP1 component responds to TNF/
IL1-induced survival and proliferation of LCs, we 
transduced LCs with shRNA specific for c-Jun, JunB 
and JunD respectively. The knockdown efficiencies 
of target genes were examined by Western blotting 
(Figure 7B). We then selected the LCs with the most 
efficient target gene knockdown for functional studies. 
Dominant negative (DN)-AP1 is a mutant form of the 
c-Jun gene repressing most of the activity of AP1. The 
effect of DN-AP1 was verified by down-regulation of 
c-Jun, a well-documented AP1 target gene (Figure 7C). 
Using CFU assay, we demonstrated that inactivation of 
c-Jun and JunB but not JunD repressed the clonogenic 
capacity of LCs (Figure 7D). LCs with either c-Jun 
or JunB knockdown showed increased sensitivity to 
NB-κB inhibitor treatment compared to Scr-shRNA-
transduced control (Figure 7E). DN-AP1 transduction 
showed much stronger effects in both repressing 
clonogenic capacity and enhancing NF-κB inhibitor 
sensitivity than knockdown any of the individual AP1 
family members (Figure 7D–7E). Most interestingly, 
LSCs and LPs in MA9-leukemia express CD117 and 
lose this surface marker during differentiation. We found 
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that DN-AP1-transduced LCs showed a differentiated 
phenotype as demonstrated by both cell morphology 
and reduced CD117 expression (Figure 7F). Therefore, 
we predicted that multiple AP1 family members might 
be involved in regulating proliferation, survival and 
differentiation of LCs downstream of JNK.
Combined inhibition of TNF and IL1 potentiated 
NF-κB inhibitor in repressing colony growth of 
primary human LCs
IL1β induces TNF-independent activation of JNK 
signaling through the RIP1-MYD88-IRAK pathway 
Figure 6: Inhibition of both TNF and IL-1 signaling could more effectively repress leukemia development in vivo 
than inactivation of either individual signaling pathway when combined with NF-κB inhibitor. WT LCs A-C. or Tnfr-/- 
LCs D-F. were transplanted into sub-lethally irradiated recipient mice. Fifteen days following transplantation, mice were treated with 
100mg/kg IL-1RA, 10 mg/kg anti-TNF, or 10mg/kg BAY individually or in combinations as indicated every day for 10 days. Survival of the 
recipient mice was analyzed by Kaplan-Meier survival graphing. Leukemia was confirmed at the time of death for each transplant mouse. 
*and ** indicate p<0.05 and p<0.01, respectively, when compared to vehicle-treated control, # indicates p<0.05 when compared to single 
or double treatment controls as determined by log-rank test. Livers were collected in a batch of recipient mice on day 28 for WT LCs (B, C) 
or day 42 for Tnfr-/- LCs (E, F) of transplantation. LC infiltration was examined by H & E staining of liver sections (B, E) and the ratio of 
liver/body weight was analyzed (C, F). In C, 1 stands for Vehicle; 2 for IL1RA; 3 for Anti-TNF; 4 for IL1RA + anti-TNF; 5 for anti-TNF + 
BAY; 6 for IL1RA + BAY; 7 for IL1RA + anti-TNF+ BAY. In F, 1 stands for Vehicle; 2 for IL1RA; 3 for BAY; 4 for IL1RA + BAY. Three 
mice from each group were analyzed. *and ** indicate p<0.05 and p<0.01, respectively, when compared to vehicle-treated control.
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[20, 21]. Caspase-1 (CASP1) is the IL1 converting enzyme 
(ICE) which is required for IL1β secretion and activity. 
CASP1 is highly expressed in the M4 and M5 subtypes 
of AML cells (Figure 8A), levels of which are correlated 
to poorer patient outcome (Figure 8B) as shown by 
analysis of the AGCT database. Increased expression of 
IL1RAP and IRAK1 as well as “elevated IRAK1-recruit 
IKK complex and Mahajan_response_to_IL1A pathway” 
is also associated with poorer prognosis of AML patients, 
while the increased expression of IRAK1BP1, a negative 
regulator of IRAK1 signaling, is correlated to better 
prognosis (Figure 8B).
To determine whether inhibition of both TNF and 
IL1 can also promote the anti-leukemic ability of NF-κB 
inhibition in primary human AML, we treated primary 
human LCs freshly isolated from peripheral blood of AML 
patients with BAY and TNF/IL-1 antagonists (Enbrel® 
and Kinaret®, respectively) individually or in combination 
in methylcellulose for CFU assay. We found that combined 
inhibition of NF-κB and TNF/IL1 did not have an additive 
Figure 7: IL-1 stimulates the activation of JNK-AP1 signaling in LCs. A. WT LCs were treated with TNF or IL1β for 15 
minutes. The activity of JNK signaling was examined by detecting the levels of p-JNK, p-Jun, p-JunB and p-JunD. B. LCs were transduced 
with shRNAs specific for c-Jun, JunB or JunD; gene knockdown efficiency was determined by Western blotting. C. The effect of DN-AP1 
transduction was verified by qRT-PCR to detect downregulation of c-Jun. D. Clonogenic capacity of gene knockdown LCs was compared 
to Scr shRNA-transduced LCs and DN-AP1-transduced LCs by CFU assay. E. The sensitivity of gene knockdown LCs to NF-κB inhibitor 
treatment was compared to Scr shRNA-transduced LCs and DN-AP1-transduced LCs by CFU assay. F. The morphology and CD117 surface 
expression were compared among the gene knockdown LCs, Scr shRNA-transduced LCs and DN-AP1-transduced LCs after 72 hours 
of suspension culture. A, B, C, F are representative of three independent trials. * indicates p<0.05 when compared with Scr-ShRNA or 
vector-transduced LCs as determined by one-way ANOVA with Bonferroni’s post-hoc test. # indicates p<0.05 between compared groups 
as determined by one-way ANOVA with Bonferroni’s post-hoc test.
Oncotarget8430www.impactjournals.com/oncotarget
Figure 8: M4/5 AML is highly susceptible to combined TNF/IL-1 and NF-κB inhibition treatment. A. High levels of 
expression of Caspase 1 in M4 and M5 subtypes of AML samples as shown by analysis of the TCGA database. B. Correlation of IL1-IRAK 
signaling to patient outcome was examined by analyzing the TCGA database. C. Primary AML cells isolated from patient peripheral blood 
or bone marrow samples were treated with indicated drugs at indicated doses in methylcellulose for CFU assay. Colonies were read after 
14 days. Results were normalized to vehicle-treated control for each patient sample. Each dot represents one patient, n=5 for each group. 
Horizontal bars represent mean, vertical bars represent one SD. *** in A indicates p<0.05 when compared to indicated groups; # indicates 
p<0.05 when compared to vehicle group; & indicates p<0.05 when compared to other groups.
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repressive effects on CFU in M0/1/2 subtypes of LCs, 
but synergized in M4/5 subtypes of LCs as well as LCs 
from AML patients secondary to MDS or therapy for other 
cancers (Figure 8C).
DISCUSSION
The inflammatory reaction has been described as 
a critical component of the tumor environment in many 
solid tumors. In these tumor tissues, chemokines secreted 
by malignant cells induce the infiltration of many types 
of hematopoietic/immune cells (such as macrophages, 
myeloid-derived suppressor cells, NK cells and T/B-
lymphocytes) to the tumor tissues. Most of the tumor-
infiltrating hematopoietic/immune cells stimulate a 
persistent cycle of damage and repair in tumor tissue to 
generate a tumor-promoting inflammation by producing 
tumor-supporting cytokines including TNF, IL1, and 
IL6. Thus, such cells and the inflammatory cytokines 
and signals generated by them have been proposed to be 
critical targets for anti-tumor therapy [22–31]. However, 
almost all of the previous studies evaluated anti-tumor 
activity by targeting these cytokines and their signaling 
pathways individually. In fact, signals stimulated by these 
cytokines are not functionally independent. Most of these 
cytokines share some common signaling pathways and 
are functionally compensatory. Thus inactivation of one 
cytokine-stimulated signal in most cases is insufficient to 
repress tumor growth due to the compensation of signaling 
stimulated by other cytokines. Our studies suggest that 
removing at least TNF and IL1 is necessary to maximally 
eliminate LCs, and especially for removing LSCs.
Consistent with earlier studies [32, 33], we found 
that the expression of TNF and IL1 is elevated in many 
subtypes of AMLs. The levels of TNF and IL1 are 
increased and correlated to poor prognosis of AML 
patients, especially older adults [5, 32, 33]. TNF is 
primarily produced by LSCs/LPs and it promotes the 
survival and proliferation of LSCs/LPs in an autocrine 
fashion [11, 16], while IL1β is mainly produced by 
LBs (Figure 3E, 3F), and also enhances the survival 
and proliferation of LSCs/LPs in a dosage-dependent 
paracrine manner. This might explain why cell density is 
so important to detect the compensatory effect of IL1 on 
TNF signaling inactivation.
An important role for IL1 in the pathogenesis of 
AML has be proposed in early studies. It was demonstrated 
that IL1 promotes the colony-forming ability of LCs by 
stimulating the activation of downstream signaling and 
the secretion of hematopoietic cytokines such as GM-CSF 
in LCs and stromal cells [34]. IL1RAP, a well-known 
co-receptor of IL1R, is highly expressed in many AML 
patient samples and may be involved in LSC self-renewal 
[35, 36]. In addition, elevated phospho-IRAK1, a hallmark 
of activated IL1 signaling, is detected in advanced MDS 
and AML patient samples, and has been suggested as 
an anti-AML target [37]. The expression levels of many 
other key components of the IL1 signaling pathway are 
also increased in AML patient samples, and such increases 
indicate a poorer patient prognosis (Figure 8). Thus the IL1 
pathway has been described as a critical therapeutic target 
for AML. However, despite of the effective repressive 
role of IL1 antagonists (such as sIL-R or IL1RA) on the 
growth of LCs in in vitro culture [38–40], inhibition of IL1 
signaling might not be able to successfully repress AML 
in vivo due to compensation by TNF-stimulated signaling.
Similar to TNF, IL1 stimulates the activation of 
both JNK and NF-κB signaling [41]. Balanced JNK and 
NF-κB signaling is critical for the proper response of 
normal tissue cells to inflammatory cytokine-stimulated 
reactions [42]. JNK induces pro-apoptotic activity in most 
normal tissues, which causes tissue damage and even 
tumor development when NF-κB signaling is inhibited. 
However, in LCs, JNK mediates a proliferation/survival 
signaling parallel to NF-κB signaling [16, 43]. Our study 
suggested a mutual compensation of IL1 and TNF activity 
in LCs by stimulating both JNK and NF-κB signaling.
Our studies suggested that combined inhibition of 
JNK and NF-κB signaling might be a better treatment for 
TNF and IL1-expressing M4/5 subtypes of AML [16]. 
Interestingly, we found that such combination treatment 
was also effective in LCs isolated from patients with 
therapy-related AMLs (Figure 8C). Such AMLs are less 
responsive to any of the current therapies and portend 
a poor prognosis. MLL rearrangements are commonly 
detected in such AML samples [44]. It will be important to 
determine whether JNK and NF-κB inhibitor combination 
treatment can effectively repress therapy-related AML in 
vivo. In addition, although our in vitro study suggested that 
the TNF/IL1 low-expressing LCs are less responsive to 
JNK and NF-κB inhibitor treatment, we predict that our 
combined inhibitor treatment might also benefit these 
AML patients when combined with standard therapies 
because TNF and IL1 can be produced by bone marrow 
niche cells during chemotherapy or radiation therapy. In 
fact, accumulated data suggest that in AML patients, the 
HSC-supporting niches are converted into inflammatory 
leukemia-promoting niches [45]. Such an inflammatory 
niche environment plays critical roles in leukemia drug-
resistance by protecting LSCs from chemotherapy [46, 
47]. Whether or not TNF/IL1-induced JNK/NF-κB 
signaling contributes to the development of drug resistance 
needs to be further verified.
Multiple potential NF-κB inhibitors such as 
the proteasome inhibitor bortezomib and the natural 
compound parthenolide have been successfully used in 
the clinical treatment setting for multiple myeloma and 
are being evaluated in clinical trials for AML treatment in 
combination with standard chemotherapeutic drugs [48, 
49]. Unfortunately, clinical grade JNK inhibitors are not 
available. We found that in these TNF/IL1-expressing AML 
cells, as is the case with inactivation of JNK signaling, 
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inhibition of both IL1 and TNF represses growth and 
significantly sensitizes clonogenic LPs and leukemogenic 
LSCs to NF-κB inhibitor treatment. Given that both TNF 
and IL1 antagonists are commonly used clinically to treat 
rheumatoid arthritis and autoimmune diseases, and have 
been confirmed to be safe, we speculate that we might able 
to use these FDA-approved TNF/IL1 antagonists and NF-
κB inhibitors to evaluate our novel treatment approach in 
AML patients. In addition, oral and intestinal mucositis are 
severe pathologic conditions affecting most patients treated 
with standard chemotherapy or radiation therapy [50–54]. 
TNF/IL1-mediated inflammation has been determined to be 
responsible for such side effects.
MATERIALS AND METHODS
Mice
The C57/Bl6J mice used as transplantation 
recipients in this study were purchased from the Jackson 
Laboratory and maintained in the Department of 
Comparative Medicine, Loyola University Chicago. All 
experiments using mice were performed according to the 
guidelines of Loyola University Medical Center and were 
approved by the Loyola University Institutional Animal 
Care and Use Committee.
Reagents
Recombinant murine-IL-3 (rm-IL-3), rm-IL-6, rm-SCF 
and rm-GM-CSF were purchased from eBioscience (San 
Diego). Recombinant human IL-3, IL-6, SCF, Flt-3, and TPO 
were obtained from Humanzyme. TNFα was purchased from 
BD Biosciences. BAY11-7085 and SP600125 small molecule 
inhibitors were purchased from Millipore. Cell lysis buffer 
(10×) was obtained from Cell Signaling, and supplemented 
with proteinase inhibitors and phosphatase inhibitors (Roche 
Diagnostics). GAPDH antibodies were obtained from Santa 
Cruz Biotechnology. c-Jun, JunB, and JunD primary and 
requisite secondary antibodies were also obtained from 
Cell Signaling. Tri-reagent used for RNA extraction was 
purchased from Sigma Aldrich. Etanercept® and Kinaret® 
were graciously provided by the hematology/oncology clinic 
at Loyola University Chicago. Methylcellulose for CFU 
assays was purchased from StemCell Technologies. Anti-
CD11b and Anti-CD117 antibodies were purchased from 
eBioscience. Wright-Geimsa solutions were purchased from 
Exaxol (Clearwater, FL).
Generation of murine leukemia cell lines
MLL-AF9 murine LCs were generated as previously 
described [16]. Briefly, CD117+ HSPCs were isolated 
from WT and Tnfr-/- mice (knockout of both Tnfr 1 and 
2) and infected with MLL-AF9-neo-expressing retrovirus. 
Infected cells were transplanted into lethally-irradiated 
recipient mice to generate leukemic mice. WT and Tnfr-/-
 LCs isolated from spleens and BM of the corresponding 
leukemic mice were used in our studies.
Colony-forming unit assay
LCs and BM cells were seeded into MethoCult GF 
M3434® (StemCell) at 1000 cells/mL (LCs) or 20,000 
cells/mL (BM HSPC), incubated at 37oC, 100% humidity, 
and 5% CO2 for 7 days (LC) or 10 days (HSPC cells). 
Numbers of colonies were counted according to the 
manufacturer’s instructions. Triplicate experiments were 
performed in all of our studies. All data were verified 
by three individual experiments. Primary AML patient 
samples were seeded into MethoCult 4035 Optimum 
without EPO and incubated at 37oC, 100% humidity, and 
5% CO2. Colonies were read 14 days following seeding.
Retroviral infection
High-titer retrovirus was produced by co-
transfecting Phoenix cells with a retroviral vector 
containing the indicated genes together with packaging 
vectors using Calphos Mammalian Transfection Kit 
(Clontech). Retroviral supernatants were harvested 24 
and 48 hours after transfection. MSCV-MLL-AF9-neo 
was kindly provided by Nancy Zeleznik-Le of Loyola 
University Chicago, and pMieg-DN-AP1 was obtained 
from Addgene. Viruses were generated using these 
retroviral vectors. LCs were transduced with such virus-
expressing genes of interest by spinoculation at 32oC, 
2000 rpm for 4 hours. Transduced cells were purified by 
FACS for Western blotting and CFU assay.
Ex vivo transplantation
Ten thousand LCs (CD45.2+) were plated in each 
well in a suspension culture and treated with indicated 
doses of BAY11-7085, SP600125, anti-TNF antibody 
(Amgen), and IL-1Ra (Anakinra, Amgen) in indicated 
combinations for 12 hours. All cells in each well were 
harvested and mixed with 106 support BM cells (CD45.1+). 
The mixed cells were equally divided and transplanted into 
10 lethally-irradiated (350cGy) recipient mice (CD45.1+). 
Mice were monitored for leukemia development by 
observing for symptoms: hunched body, significant weight 
loss, or hind-limb paralysis. Leukemia was confirmed by 
examining CD45.2+ LCs in PB, spleen and BM, as well as 
liver and kidney infiltration.
In vivo transplantation and treatment
Two thousand LCs were transplanted into sub-lethally 
irradiated (350cGy) C57BL6/J mice via tail vein injection. 
Twenty days after transplantation, mice were treated with 
10mg/kg InVivoMAb anti m-TNFα (BioXcell), 10 mg/kg 
BAY11-7085, 30 mg/kg SP600125, or IL-1RA (Anakinra, 
Amgen) individually or in combinations every day for 10 
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days. Mice were monitored for leukemia development by 
observing for lethargy, paralysis, significant weight loss 
and/or enlarged abdomen. Leukemia was verified after the 
mice were sacrificed by examining for infiltration of LCs 
into livers, lungs and spleens.
shRNA knockdown
LCs were transduced with retrovirus-expressing 
shRNAs (Origene) specifically targeted to c-Jun 
(TG501139), JunB (TG516091), JunD (TG501140), and IL-
1R (TG501076). The transduced cells were selected for one 
week using puromycin (c-Jun shRNA) or by GFP sorting 
(JunB, JunD, IL-1R) to obtain stably transduced cells. 
Knockdown efficiency was examined by Western blotting 
(c-Jun, JunB, JunD), or RT-PCR (IL-1R). Scrambled 
shRNAs were transduced and studied in parallel as controls.
Primary human AML samples
Peripheral blood samples from AML patients were 
obtained from the clinic at Loyola University Medical Center 
in accordance with the IRB protocol. Leukemic blasts in PB 
of all patients were 30-90% when samples were collected. 
Samples were processed for mono-nuclear cells (MNC) 
by Ficoll-paque gradient centrifugation. A portion of MNC 
was used for RNA extraction and TNF expression analysis; 
another fraction of MNC was plated in StemSpan serum-
free medium (StemCell) supplemented with recombinant 
human SCF (100 ng/mL), Flt-3L (100 ng/mL), TPO (20 ng/
mL), IL-6 (20 ng/mL), and IL-3 (20 ng/mL). Cytokines were 
obtained from Humanzyme. Following overnight culturing, 
3×105 cells from each sample were harvested and treated with 
the indicated doses of BAY11-7085, anti-TNF (Etanercept®), 
or anti-IL1 (Kinaret®), and plated into methylcellulose 
(StemCell) for CFU assay. Colonies were read after 14 days. 
In addition, serum was collected from the same patients for 
examination of TNF and other cytokines.
Liver/body ratio and liver histologic analysis
Livers were collected from mice at indicated time 
points and weighed. The ratio of liver/body weight was 
calculated. Livers were fixed in zinc formalin at room 
temperature for 3 days. Tissues were then transferred into 
70% ethanol until embedding. Embedding and cutting of 
sections were performed according to standard protocols 
of the Pathology Department, Loyola University Medical 
Center. Slides were then stained with H&E.
Annexin-V and 7-AAD staining to analyze for 
apoptosis
LCs with indicated treatments were collected and 
stained with allophycocyanin-conjugated Annexin-V 
followed by 7-amino-actinomycin D (7-AAD) staining in 
binding buffer following the manufacturer’s instructions 
(BD Biosciences). Death of infected cells was examined 
for the percentages of Annexin-V+ and Annexin-
V+/7AAD+ cells by flow cytometry.
Statistical analysis
One-way ANOVA with Bonferonni post-hoc test 
was used for all in vitro comparisons, except where 
otherwise noted. Log-rank test was used for all in vivo 
comparisons. All statistical analyses were performed using 
Graphpad Prism software.
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